版本:
中国

BRIEF-Teva interim CEO sees more headcount reductions

May 11 Teva Pharmaceutical Industries Ltd

* Interim CEO: headcount reduced by 5,000 since Actavis deal, expects more cuts by end of 2017

* Interim CEO: deteriorating situation in Venezuela could impact ability to produce products there Further company coverage: (Reporting by Tova Cohen)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐